Investors

Press Releases

 
Press Releases
  Date Title View
Jul 13, 2016
JERSEY CITY, N.J., July 13, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that the Company has entered into an Asset Purchase agreement with UK-based Cypralis Limited, a life sciences company focused on the discovery of novel therapeutics based on modulation of peptidyl-prolyl isome...
Jul 6, 2016
JERSEY CITY, N.J., July 06, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at Cantor Fitzgerald's 2nd Annual Healthcare Conference at Le Parker Meridien New York on Tuesday, July 12, 2016 at 9:00 a.m. ET. A live webcast will...
Jun 21, 2016
JERSEY CITY, N.J., June 21, 2016 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq:SCYX) today announced the pricing of its underwritten public offering of 9,375,000 shares of its common stock and warrants to purchase 4,218,750 shares of its common stock. The shares and warrants are being sold at a public offering price of $2.40 per share sold in t...
Jun 20, 2016
JERSEY CITY, N.J., June 20, 2016 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that it has commenced an underwritten public offering of shares of its common stock and warrants to purchase shares of its common stock. The company expects to grant the underwriter a 30-day option to purchase additional shares of its common sto...
Jun 20, 2016
SCY-078 shown to be the first glucan synthase inhibitor with high oral bioavailability in humansFungicidal activity of SCY-078 demonstrated against multiple Candida species, including difficult-to-treat strainsSCY-078 progressing to next stages of clinical development in invasive candidiasis with bot...
Jun 10, 2016
JERSEY CITY, N.J., June 10, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) announced today that results of one Phase 1 study and one nonclinical study of the company's lead clinical drug candidate, SCY-078, will be presented in podium presentations at ASM Microbe 2016 that will take place from June 16 throug...
Jun 8, 2016
Confirmation of Clinically Relevant Antifungal Activity of SCY-078 in Patients with Candida Infections Company to Host a Conference Call Today at 5:00pm ET to Discuss Results JERSEY CITY, N.J., June 08, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCY...
May 13, 2016
JERSEY CITY, N.J., May 13, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company's novel and structurally distinct glucan synthase inhibitor, SCY-078, for the treatment of invasive Candida infe...
May 9, 2016
JERSEY CITY, N.J., May 09, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today reported financial results for the quarter ended March ...
Apr 19, 2016
JERSEY CITY, N.J., April 19, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) announced today that the Company has been granted Small and Medium Sized Enterprise (SME) status by the European Medicines Agency (EMA). The SME designation was created by the EMA to bolster innovation and su...
FirstPrevious
3
... NextLast
= add release to Briefcase